Prelude Therapeutics Inc

+1.55 (+4.57%)
Earnings Announcements

Prelude Therapeutics Q2 Loss Per Share $0.58

Published: 08/12/2021 11:47 GMT
Prelude Therapeutics Inc (PRLD) - Q2 Loss per Share $0.58.
Q2 Earnings per Share Estimate $-0.49 -- Refinitiv Ibes Data (analyst estimates).
Cash and Cash Equivalents As of June 30, 2021 Were $343.1 Million.
Prelude Therapeutics - Believes Current Cash, Cash Equivalents Will Be Sufficient to Fund Operating Expenses & Capex Requirements Into Mid-2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.63

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.66

More details on our Analysts Page.